EGFR and head and neck cancer: These studies led to the regulatory approval of these EGFR-targeting agents for treating colorectal, lung, and head and neck cancers in combination with conventional chemotherapy or radiotherapy; however, despite the objective responses, the overall response rate of patients treated with EGFR-targeted therapy is low, particularly when these EGFR-targeting agents are used as monotherapies [10]–[12].